JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Cholestatic liver diseases including primary biliary cholangitis (PBC) are associated with active hepatic fibrogenesis, which ultimately progresses to cirrhosis. Activated hepatic stellate cells (HSCs) are the main fibrogenic effectors in response to cholangiocyte damage. JCAD regulates cell proliferation and malignant transformation in nonalcoholic steatoheaptitis-associated hepatocellular carcinoma (NASH-HCC). However, its participation in cholestatic fibrosis has not been explored yet. Methods: Serial sections of liver tissue of PBC patients were stained with immunofluorescence. Hepatic fibrosis was induced by bile duct ligation (BDL) in wild-type (WT), global JCAD knockout mice (JCAD-KO) and HSC-specific JCAD knockout mice (HSC-JCAD-KO), and evaluated by histopathology and biochemical tests. In situ-activated HSCs isolated from BDL mice were used to determine effects of JCAD on HSC activation. Results: In consistence with staining of liver sections from PBC patients, immunofluorescent staining revealed that JCAD expression was identified in smooth muscle α-actin (α-SMA)-positive fibroblast-like cells and was significantly up-regulated in WT mice with BDL. JCAD deficiency remarkably ameliorated BDL-induced hepatic injury and fibrosis, as documented by liver hydroxyproline content, when compared to WT mice with BDL. Histopathologically, collagen deposition was dramatically reduced in both JCAD-KO and HSC-JCAD-KO mice compared to WT mice, as visualized by Trichrome staining and semi-quantitative scores. Moreover, JCAD deprivation significantly attenuated in situ HSC activation and reduced expression of fibrotic genes after BDL. Conclusions: JCAD deficiency effectively suppressed hepatic fibrosis induced by BDL in mice, and the underlying mechanisms are largely through suppressed Hippo-YAP signaling activity in HSCs.
Abstract
Background/Aims: Cholestatic liver diseases including primary biliary cholangitis (PBC) are associated with active hepatic fibrogenesis, which ultimately progresses to cirrhosis. Activated hepatic stellate cells (HSCs) are the main fibrogenic effectors in response to cholangiocyte damage. JCAD regulates cell proliferation and malignant transformation in nonalcoholic steatoheaptitis-associated hepatocellular carcinoma (NASH-HCC). However, its participation in cholestatic fibrosis has not been explored yet. Methods: Serial sections of liver tissue of PBC patients were stained with immunofluorescence. Hepatic fibrosis was induced by bile duct ligation (BDL) in wild-type (WT), global JCAD knockout mice (JCAD-KO) and HSC-specific JCAD knockout mice (HSC-JCAD-KO), and evaluated by histopathology and biochemical tests. In situ-activated HSCs isolated from BDL mice were used to determine effects of JCAD on HSC activation. Results: In consistence with staining of liver sections from PBC patients, immunofluorescent staining revealed that JCAD expression was identified in smooth muscle α-actin (α-SMA)-positive fibroblast-like cells and was significantly up-regulated in WT mice with BDL. JCAD deficiency remarkably ameliorated BDL-induced hepatic injury and fibrosis, as documented by liver hydroxyproline content, when compared to WT mice with BDL. Histopathologically, collagen deposition was dramatically reduced in both JCAD-KO and HSC-JCAD-KO mice compared to WT mice, as visualized by Trichrome staining and semi-quantitative scores. Moreover, JCAD deprivation significantly attenuated in situ HSC activation and reduced expression of fibrotic genes after BDL. Conclusions: JCAD deficiency effectively suppressed hepatic fibrosis induced by BDL in mice, and the underlying mechanisms are largely through suppressed Hippo-YAP signaling activity in HSCs.
참고문헌 (36)
- Zeng N, "Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region : a systematic review and meta-analysis", Hepatol Int, 13, pp.788~799 (2019)
- McGee EE, "Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults", Int J Cancer, 144, pp.707~717 (2019)
- Friedman SL, "Hepatic fibrosis 2022 : Unmet needs and a blueprint for the future", Hepatology, 75, pp.473~488 (2022)
- Gonzalez-Sanchez E, "Nuclear receptors in acute and chronic cholestasis", Dig Dis, 33, pp.357~366 (2015)
- Zollner G, "Role of nuclear receptors in the adaptive response to bile acids and cholestasis : pathogenetic and therapeutic considerations", Mol Pharm, 3, pp.231~251 (2006)
- Wu J, "tomm22 knockdown-mediated hepatocyte damages elicit both the formation of hybrid hepatocytes and biliary conversion to hepatocytes in zebrafish larvae", Gene Expr, 17, pp.237~249 (2017)
- Glaser SS, "Cholangiocyte proliferation and liver fibrosis", Expert Rev Mol Med, 11, pp.e7~ (2009)
- Matsumoto K, "Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro : interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro", Hepatology, 20, pp.376~382 (1994)
- Mederacke I, "Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology", Nat Commun, 4, pp.2823~ (2013)
- Friedman SL, "Mechanisms of hepatic fibrogenesis", Gastroenterology, 134, pp.1655~1669 (2008)
- Friedman SL, "Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury", J Biol Chem, 275, pp.2247~2250 (2000)
- Akashi M, "A coronary artery disease-associated gene product, JCAD", KIAA1462, is a novel component of endothelial cell-cell junctions, 2011, pp.413, 224~229
- Hara T, "Targeted disruption of JCAD(junctional protein associated with coronary artery disease)", KIAA1462, a coronary artery diseaseassociated gene product, inhibits angiogenic processes in vitro and in vivo, 2017, pp.37, 1667~1673
- Jones PD, "JCAD, a Gene at the 10p11 coronary artery disease locus, regulates hippo signaling in endothelial cells", Arterioscler Thromb Vasc Biol, 38, pp.1711~1722 (2018)
- Xu S, "The novel coronary artery disease risk gene JCAD", KIAA1462 promotes endothelial dysfunction and atherosclerosis, 2019, pp.40, 2398~2408
- Ye J, "JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity", Cancer Res, 77, pp.5287~5300 (2017)
- Du SL, "Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats", J Pharmacol Exp Ther, 322, pp.560~568 (2007)
- Zhan SS, "Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo", Hepatology, 43, pp.435~443 (2006)
- Li X, "GPR91, a critical signaling mechanism in modulating pathophysiologic processes in chronic illnesses", FASEB J, 34, pp.13091~13105 (2020)
- Kong M, "Ablation of serum response factor in hepatic stellate cells attenuates liver fibrosis", J Mol Med(Berl), 97, pp.1521~1533 (2019)
- Li M, "Hepatic stellate cellspecific deletion of SIRT1 exacerbates liver fibrosis in mice", Biochim Biophys Acta Mol Basis Dis, 1863, pp.3202~3211 (2017)
- De Vos R, "Ultrastructural characteristics of novel epithelial cell types identified in human pathologic liver specimens with chronic ductular reaction", Am J Pathol, 140, pp.1441~1450 (1992)
- Olsen AL, "Hepatic stellate cells require a stiff environment for myofibroblastic differentiation", Am J Physiol Gastrointest Liver Physiol, 301, pp.G110~G118 (2011)
- Kastan N, "Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues", Nat Commun, 12, pp.3100~ (2021)
- O’Hara SP, "The dynamic biliary epithelia : molecules, pathways, and disease", J Hepatol, 58, pp.575~582 (2013)
- Yanguas SC, "Experimental models of liver fibrosis", Arch Toxicol, 90, pp.1025~1048 (2016)
- Wells RG, "The portal fibroblast : not just a poor man’s stellate cell", Gastroenterology, 147, pp.41~47 (2014)
- Yoshida K, "Differential regulation of TGF-β", Smad signaling in hepatic stellate cells between acute and chronic liver injuries, 2012, pp.3, 53~
- Grannas K, "Crosstalk between Hippo and TGFβ : Subcellular Localization of YAP", TAZ, J Mol Biol, pp.2015, 427[DOI]
- Williams EJ, "Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells", J Hepatol, 32, pp.754~761 (2000)
- Du K, "Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells", Gastroenterology, 154, pp.1465~1479 (2018)
- Mannaerts I, "The Hippo pathway effector YAP controls mouse hepatic stellate cell activation", J Hepatol, 63, pp.679~688 (2015)
- Lu ZN, "Pantoprazole ameliorates liver fibrosis and suppresses hepatic stellate cell activation in bile duct ligation rats by promoting YAP degradation", Acta Pharmacol Sin, 42, pp.1808~1820 (2021)
- Liberale L, "JCAD promotes arterial thrombosis through PI3K", Akt modulation : a translational study, 2023, pp.44, 1818~1833
- Cui X, "F‑actin cytoskeleton reorganization is associated with hepatic stellate cell activation", Mol Med Rep, 9, pp.1641~1647 (2014)
- Lua I, "Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers", J Hepatol, 64, pp.1137~1146 (2016)